Tougher regulatory environment for biopharma? Debate ensues
Onlookers beware: trying to interpret how rigid or lax the current FDA drug approval landscape might be based on a couple of seemingly inter-related approvals or rejections can be a fool’s errand.
But what about when this seemingly tougher approval environment is met with an FTC ready to pounce on any biotech merger, and Congress is poised to actually do something on drug prices soon? Well, that may be a different story, according to SVB Leerink’s biotech analyst Geoffrey Porges.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.